Pfizer CEO Sells Stock Same Day Positive Results of COVID-19 Vaccine Announced
Story Highlights On Nov. 9, 2020, Pfizer released preliminary Phase 3 clinical trial data indicating that its experimental mRNA COVID-19 vaccine is 90 percent effective, triggering a big surge in stock price. Pfizer CEO Albert Bourla immediately sold 60 percent of his company stock, realizing a gain of $5.6 million in what the company called […]
Another Shot at a Vaccine for Lyme Disease
The U.S. National Institutes of Health (NIH) has provided the University of Maryland with a $3.5 million dollar grant to develop a vaccine for Lyme disease.1 Principal investigators Utal Pal, PhD, professor at the Virginia-Maryland College of Veterinary Medicine at the University of Maryland College of Agriculture and Natural Resources and Matthias Schnell, PhD, director […]
Facebook Bans Ads “Discouraging” Vaccination
Facebook has announced that the company is implementing a new global policy banning paid advertisements on its platform that it has determined discourage people from getting vaccinated.1 According to a blog authored by Kang-Xing Jin, Head of Health and Rob Leathern, Director of Product Management at Facebook: Today, we’re launching a new global policy that […]
Flu Shot Deaths in South Korea Said to Be “Coincidental”
Story Highlights More than 80 people have died in South Korea following influenza vaccination. After an investigation into the safety of the vaccines, South Korean health authorities ruled the deaths as “coincidental.” The public health agency in South Korea has decided to continue and promote its free influenza vaccine program despite public anxiety relating to […]
New York Bar Calls for COVID-19 Vaccine Mandate and Promotion
Opinion | The New York State Bar Association (NYSBA) House of Delegates approved resolutions on Nov. 7, 2020 that included urging the state to consider mandating a COVID-19 vaccine once “scientific consensus” emerges that it is safe, effective and necessary.1 The NYSBA also called for a number of other legal reforms and public health measures related […]
CureVac’s COVID-19 Vaccine Produces Grade 3 Adverse Events
Biopharmaceutical company CureVac NV of Tübingen, Germany has released the interim results of its Phase 1 clinical trial on its experimental CVnCoV vaccine COVID-19. The vaccine, which was given to more than 250 healthy adults 18 to 60 years of age, is based on messenger ribonucleic acid (mRNA) technology.1 2 Unlike traditional vaccines, mRNA vaccines […]